60 Degrees Pharmaceuticals, Inc
SXTP
Positions held
Your positionsSXTP isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $3.42M | Enterprise value | $12.03M | Trailing P/E | — | Forward P/E | -0.27 |
| PEG | — | Price / book | -0.37 | Beta | 2.40 | Dividend yield | 0.00% |
| Revenue growth | -32.5% | Earnings growth | — | Gross margin | -1.7% | Operating margin | -10.9% |
| Profit margin | 0.0% | ROE | -3.3% | ROA | -127.1% | Debt / equity | 0.06 |
| Current ratio | 2.33 | Free cash flow | -$6.08M | Analyst recommendation | none | Mean target | $3.70 |
| 52w high | $8.62 | 52w low | $0.84 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.2M | $0.2M | $0.3M | $0.4M | $0.1M | — |
| Op margin | -1092.4% | -1292.5% | -632.0% | -531.4% | -1591.5% | — |
| Net income | -$2.3M | -$2.1M | -$1.4M | -$2.3M | -$1.7M | — |
| Gross margin | 27.3% | 47.1% | 60.2% | -22.9% | 50.4% | — |
| Gross profit | $0.1M | $0.1M | $0.2M | -$0.1M | $0.1M | — |
| Operating income | -$2.3M | -$2.1M | -$1.9M | -$2.3M | -$1.6M | — |
- Revenue +28% vs prior quarter ($0.2M vs $0.2M).
- Gross margin 27.3% (was 47.1% prior quarter).
- Operating margin expanded to -1092.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.0M | $0.6M | $0.3M | $0.2M | — |
| Op margin | -771.6% | -1599.0% | -2032.8% | -784.2% | — |
| Net income | -$7.4M | -$7.9M | -$3.8M | -$6.2M | — |
| Gross margin | 22.3% | 36.7% | -87.1% | -93.7% | — |
| Gross profit | $0.2M | $0.2M | -$0.2M | -$0.2M | — |
| Operating income | -$7.8M | -$9.7M | -$5.2M | -$1.8M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · 60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting
2026-09-03 · 60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
2026-08-14 · 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
2026-08-11 · Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
2026-08-06 · Merck KGaA (MKKGY) Misses Q2 Earnings Estimates
2026-07-30 · 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
Price (daily)
Full chart · RSI · MACD · patterns